Cytori Therapeutics Inc., of Austin, Texas, has changed its name to Plus Therapeutics Inc. Its ticker symbol on the Nasdaq Capital Market and for its series S warrants is now PSTV. The company plans a 1-for-50 reverse stock split on Aug. 5. The number of outstanding shares of its common stock is anticipated to change from about 22.2 million to approximately 400,000.

Holding an inter partes review (IPR) of a patent granted before the 2012 implementation of the America Invents Act, which invented the IPR, is not an unconstitutional taking under the Fifth Amendment, the U.S. Court of Appeals for the Federal Circuit ruled Tuesday in Celgene Corp. v. Laura Peter. 

Incyte Corp., of Wilmington, Del., said for the second quarter, net product revenues of Jakafi (ruxolitinib) were $410 million as compared to $346 million for the same period in 2018, representing 18% growth.

Tetra Bio-Pharma Inc., of Ottawa, Ontario, said it intends to complete a non-brokered private placement offering, where some of the corporation's directors, officers, consultants and employees, as well of certain of their associates, will purchase an aggregate of 870,000 units at CA0.30 each for aggregate gross proceeds of CA$261,000 (US$197,750). 

Teva Pharmaceutical Industries Ltd. agreed to pay the state of California $69 million in what California Attorney General Xavier Becerra Monday called the largest pay-for-delay settlement received by any state. 

Ziopharm Oncology Inc., of Boston, said it entered into an agreement with existing investors for the exercise of previously issued warrants to purchase common stock in a private placement, being led by existing stockholder, MSD Partners LP, that is expected to result in gross proceeds of approximately $45 million. 

Alvotech ehf, of Reykjavik, Iceland and Cipla Gulf FZ LLC, a wholly-owned subsidiary of Mumbai-based Cipla Ltd., said they have entered into an exclusive partnership for the commercialization of AVT-02, a MAb biosimilar to Humira (adalimumab, Abbvie Inc.), in select emerging markets.